IP Library › Granted Patent US 12,528,781
Granted Patent B2
US 12,528,781 · App. 18/534,517 · Granted Jan 20, 2026

Heterocyclic GLP-1 agonists

Inventors: Qinghua Meng (Shanghai, CN); Hui Lei (Shanghai, CN); Haizhen Zhang (Shanghai, CN); Xichen Lin (Shanghai, CN); Andrew Jennings (South San Francisco, CA)
Assignee: Gasherbrum Bio, Inc.
C07D273/01A61K9/0053A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,528,781
App. No.
18/534,517
Granted
Jan 20, 2026
Kind
B2
Abstract

This disclosure relates to GLP-1 agonists of Formula I: including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Claims (181)

1 . A compound, or a pharmaceutically acceptable salt or solvate thereof, selected from the group consisting of:

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169a

169b

170b

170a

171b

171a

172a

172b

173a

173b

174

175

176

177

178

179

180

181

182

183

184

185

186a

187a

188

189

190

191

192

193

195

196

197

198a

199a

200

201

202

203

204

205a

206a

207a

208a

209a

210a

211

212

213

214

215a

216a

217a

218a

219

220

221

222a

223

224

225a

226a

227

228

229

230

231

232

233

234a

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249a

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

269a

269b

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

2 . A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

3 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

4 . A compound which is:

or a pharmaceutically acceptable salt thereof.

5 . A compound which is:

6 . A pharmaceutical composition comprising the compound of claim 4 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

7 . A compound which is:

or a pharmaceutically acceptable salt thereof.

8 . A compound which is:

9 . A pharmaceutical composition comprising the compound of claim 7 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

10 . A compound which is:

or a pharmaceutically acceptable salt thereof.

11 . A compound which is:

12 . A pharmaceutical composition comprising the compound of claim 10 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

13 . A compound which is:

or a pharmaceutically acceptable salt thereof.

14 . A compound which is:

15 . A pharmaceutical composition comprising the compound of claim 13 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

16 . A compound which is:

or a pharmaceutically acceptable salt thereof.

17 . A compound which is:

18 . A pharmaceutical composition comprising the compound of claim 16 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

19 . A compound which is:

or a pharmaceutically acceptable salt thereof.

20 . A compound which is:

21 . A pharmaceutical composition comprising the compound of claim 19 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2024
From: JENNINGS, ANDREW
To: SHOUTI INC.
Reel/Frame 067660/0357 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2024
From: SHOUTI INC.
To: GASHERBRUM BIO, INC.
Reel/Frame 067660/0360 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2024
From: MENG, QINGHUA; LEI, HUI; ZHANG, HAIZHEN; LIN, XICHEN
To: SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD.
Reel/Frame 067660/0394 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2024
From: SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD.
To: GASHERBRUM BIO, INC.
Reel/Frame 067660/0403 →
Priority Claims (2)
WO PCT/CN2020/107437 · Aug 6, 2020 · international
WO PCT/CN2021/073958 · Jan 27, 2021 · international
Continuity (3)
Continuation 18106378 · Feb 6, 2023
Continuation PCTCN2021111193 · Aug 6, 2021
Related Publication 20240376061A1 · Nov 14, 2024
References Cited (99)
US 11926626B2 · Meng et al. · 2024 [cited by applicant]
US 20080280933A1 · Efremov et al. · 2008 [cited by applicant]
US 20180170908A1 · Aspnes et al. · 2018 [cited by applicant]
US 20190276465A1 · Xu · 2019 [cited by applicant]
US 20190382384A1 · Aspnes et al. · 2019 [cited by applicant]
US 20190382387A1 · Aspnes et al. · 2019 [cited by applicant]
US 20230071840A1 · Meng et al. · 2023 [cited by applicant]
US 20230107793A1 · Meng et al. · 2023 [cited by applicant]
US 20230165846A1 · Meng et al. · 2023 [cited by applicant]
US 20230192633A1 · Meng et al. · 2023 [cited by applicant]
US 20230295154A1 · Meng et al. · 2023 [cited by applicant]
US 20230391760A1 · Meng et al. · 2023 [cited by applicant]
US 20240083886A1 · Meng et al. · 2024 [cited by applicant]
US 20240246962A1 · Meng et al. · 2024 [cited by applicant]
CN 108017636 · 2018 [cited by applicant]
CN 108430998 · 2018 [cited by applicant]
CN 109790161A · 2019 [cited by applicant]
CN 110325530 · 2019 [cited by applicant]
CN 112533674A · 2021 [cited by applicant]
CN 113480534 · 2021 [cited by applicant]
CN 113493447 · 2021 [cited by applicant]
CN 113773310 · 2021 [cited by applicant]
CN 113801136 · 2021 [cited by applicant]
CN 113816948 · 2021 [cited by applicant]
CN 113831337 · 2021 [cited by applicant]
CN 114591296 · 2022 [cited by applicant]
CN 114591308 · 2022 [cited by applicant]
CN 114634510 · 2022 [cited by applicant]
CN 114716423 · 2022 [cited by applicant]
CN 114761395A · 2022 [cited by applicant]
CN 114763352 · 2022 [cited by applicant]
CN 114907351 · 2022 [cited by applicant]
CN 115594669A · 2023 [cited by applicant]
CN 115884969A · 2023 [cited by applicant]
WO WO2004026305 · 2004 [cited by applicant]
WO WO2005002503A2 · 2005 [cited by applicant]
WO WO2006102610 · 2006 [cited by applicant]
WO WO2007146122 · 2007 [cited by applicant]
WO WO2008137770A1 · 2008 [cited by applicant]
WO WO2008153701 · 2008 [cited by applicant]
WO WO2009143039A2 · 2009 [cited by applicant]
WO WO2010065674A1 · 2010 [cited by applicant]
WO WO2011068821 · 2011 [cited by applicant]
WO WO2018056453A1 · 2018 [cited by applicant]
WO WO2018085148A1 · 2018 [cited by applicant]
WO WO2018109607A1 · 2018 [cited by applicant]
WO WO2018157857A1 · 2018 [cited by applicant]
WO WO2019239319A1 · 2019 [cited by applicant]
WO WO2019239371 · 2019 [cited by applicant]
WO WO2020103815 · 2020 [cited by applicant]
WO WO2020207474 · 2020 [cited by applicant]
WO WO2020234726 · 2020 [cited by applicant]
WO WO2020263695 · 2020 [cited by applicant]
WO WO2021018023 · 2021 [cited by applicant]
WO WO2021081207 · 2021 [cited by applicant]
WO WO2021096284 · 2021 [cited by applicant]
WO WO2021096304 · 2021 [cited by applicant]
WO WO2021112538 · 2021 [cited by applicant]
WO WO2021154796 · 2021 [cited by applicant]
WO WO2021160127 · 2021 [cited by applicant]
WO WO2021187886 · 2021 [cited by applicant]
WO WO2021197464 · 2021 [cited by applicant]
WO WO2021219019 · 2021 [cited by applicant]
WO WO2021244645 · 2021 [cited by applicant]
WO WO2021249492 · 2021 [cited by applicant]
WO WO2021254470 · 2021 [cited by applicant]
WO WO2021259309A1 · 2021 [cited by applicant]
WO WO2022007979 · 2022 [cited by applicant]
WO WO2022028572 · 2022 [cited by applicant]
WO WO2022031994 · 2022 [cited by applicant]
WO WO2022040600 · 2022 [cited by applicant]
WO WO2022042691 · 2022 [cited by applicant]
WO WO2022048665A1 · 2022 [cited by applicant]
WO WO2022068772 · 2022 [cited by applicant]
WO WO2022078152 · 2022 [cited by applicant]
WO WO2022078380 · 2022 [cited by applicant]
WO WO2022078407 · 2022 [cited by applicant]
WO WO2022109182 · 2022 [cited by applicant]
WO WO2022111624 · 2022 [cited by applicant]
WO WO2022135572 · 2022 [cited by applicant]
WO WO2022165076 · 2022 [cited by applicant]
WO WO2022192428 · 2022 [cited by applicant]
WO WO2022192430 · 2022 [cited by applicant]
WO WO2022199458 · 2022 [cited by applicant]
WO WO2022199661 · 2022 [cited by applicant]
WO WO2022202864 · 2022 [cited by applicant]
WO WO2022216094 · 2022 [cited by applicant]
WO WO2022219495A1 · 2022 [cited by examiner]
WO WO2022228490A1 · 2022 [cited by applicant]
WO WO2023138684A1 · 2023 [cited by applicant]
WO WO2023151574A1 · 2023 [cited by applicant]
WO WO2023151575A1 · 2023 [cited by applicant]
WO WO2023179542A1 · 2023 [cited by applicant]
WO WO2023198140A1 · 2023 [cited by applicant]
Database Registry Chemical Abstracts Service; Sep. 21, 2008, Anonymous: “1-Ethyl-2-[[[5-[[5-(3-thienyl)-2H-tetrazo1-2-y1]methyl]-1, 3, 4-oxadiazol-2-yl]thio]methyl]-1H-benzimidazole-5-carboxylic acid” Database accession… [cited by applicant]
ACS STN. RN 1290110-76-7, 1228633-44-0, 1228554-41-3. STN Registry. May 4, 2011. 2 pages. [cited by applicant]
GLP-1 Receptor Agonists—The Johns Hopkins Patient Guide to Diabetes (hopkinsdiabetesinfo.org), https://hopkinsdiabetesinfo.org/medications-for-type-2-diabetes-glp-1-agonists/. [cited by applicant]
GLP-1 agonists: Diabetes drugs and weight loss—Mayo Clinic. [cited by applicant]
International Search Report and Written Opinion for PCT/CN2021/111193 dated Nov. 8, 2021, 9 pages. [cited by applicant]